Camurus is a Swedish science-led pharmaceutical company committed to developing and commercializing innovative and long-acting medicines for the treatment of severe and chronic diseases.
On-demand webinar - The opioid dependence treatment landscape is changing: What every GP needs to know
In this on-demand webinar we explore the new era in opioid dependence treatment and unpack the implications of these transformative changes, highlighting how they democratise access to treatments, including long-acting injectable buprenorphine (LAIB). While LAIBs play a critical role, they are part of a broader treatment landscape.
[Expert video | Duration: 15:52] Addiction medicine specialist Professor Nick Lintzeris discusses the key elements of assessing and managing opioid dependence, and outlines the options available for MATOD (medication-assisted treatment of opioid dependence) in general practice.
Module 1 of 2: This learning module explores the nature of opioid dependence and the diagnostic criteria for opioid use disorder, then outlines the use of pharmacotherapies in medication assisted treatment of opioid dependence (MATOD) and the benefits of opioid agonist treatment including long-acting injectable buprenorphine (LAIB) products.
Module 2 of 2: This two-part activity provides education on the various long-acting buprenorphine (LAIB) formulations available in Australia, followed by a practical exercise where the learner goes through the steps of assessing whether a patient is suitable for LAIB treatment, and discusses with them how treatment may help them achieve their goals.